HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Greater collaboration, understanding of disease biology may improve outcomes in pancreatic cancer
• American Cancer Society honors three from Fox Chase
• Apatorsen combination improves survival in metastatic bladder cancer
• ASCO, Society of Gynecologic Oncology issue guideline for neoadjuvant chemotherapy use in ovarian cancer
• ASH elects four to executive committee
• Association of Community Cancer Centers presents clinical research award
• Association of Pediatric Hematology/Oncology Nurses presents mentoring award
• Custirsen plus docetaxel fails to extend OS in NSCLC
• Dana-Farber Cancer Institute names chief nursing officer
• Fox Chase Cancer Center appoints two to anesthesiology department
• Letermovir prevents clinically significant cytomegalovirus infection in high-risk HSCT recipients
• Moffitt Cancer Center appoints co-leader of immunology program
• NYU Langone Medical Center researcher receives award from NCI
• Olaparib maintenance prolongs PFS in women with BRCA–mutated ovarian cancer
• Palliative care nurse receives excellence award
• Physician–scientist joins NewYork-Presbyterian/Columbia University Medical Center
• Study results serve as ‘call to action’ to increase investment in palliative care
• Value of data from Nurses’ Health Study ‘cannot be underestimated’
• Vanderbilt radiation oncologist elected board president
• Xgeva demonstrates noninferiority in delaying time to bone complications in multiple myeloma
• Personalized medicine for medicated persons Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA approves Tecentriq for certain patients with metastatic lung cancer
• FDA awards 21 grants for orphan drugs
• FDA grants orphan drug designation to veliparib for advanced NSCLC
• FDA grants priority review to brigatinib for ALK–positive NSCLC
• Caution: Do not hold on to Medicare overpayments
• Active surveillance feasible for majority of favorable-risk prostate cancers
• Adjuvant chemotherapy associated with improved OS in stage II colorectal cancer
• Caregiver well-being associated with perceived quality of care for patients with lung, colorectal cancers
• CDC: Breast cancer mortality rates remain higher among black women
• Children with cancer often receive high-intensity end-of-life care
• Donor sex, age may affect red blood cell transfusion outcomes
• Emicizumab reduces bleeding in patients with severe hemophilia A
• Extreme use of testing common among older women with metastatic breast cancer
• Fecal microbiota transplant effective for GVHD after stem cell transplantation
• Financial incentives help low-income adults quit smoking
• First-line chemotherapy prolongs survival in adults with medulloblastoma
• Higher SPF sunscreen reduces risk for melanoma by 33%
• Higher vitamin D concentrations decrease cancer risk among older women
• Interim PET-CT may safely guide adapted treatment for Hodgkin lymphoma
• Many esophageal cancers missed after negative endoscopy in patients with Barrett's esophagus
• Maternal birthplace may affect offspring cancer risk
• Mindfulness, stress management reduce physician burnout
• New-generation TKIs for CML increase risk for cardiovascular events
• New guidelines urge colonoscopy surveillance after CRC resection
• Ovarian cancer surveillance with CA-125 tests, CT scans common despite lack of proven benefit
• Patients, physicians hold different views of myeloproliferative neoplasm prognosis, treatment goals
• Prolonged nightly fasting may reduce breast cancer recurrence risk
• Removal of 18 lymph nodes associated with improved OS in mucosal HNSCC
• Sexual dysfunction common among patients with myeloproliferative neoplasms
• Sickle cell trait increases risk for rhabdomyolysis, not death
• Successful patient–physician communication navigates emotional ‘roller coaster’ of new treatment era
• Task force recommends routine colorectal cancer screening for adults aged 50 to 75 years
• Uridine triacetate serves as antidote for capecitabine, 5-FU overexposure
• USPSTF breast cancer screening recommendations remain unchanged despite controversy
• Adjuvant sunitinib extends DFS in high-risk renal cell carcinoma
• Custirsen fails to improve survival in castration-resistant prostate cancer
• Daratumumab combination improves PFS, ORR in relapsed, refractory multiple myeloma
• Eltrombopag increases rate of hematologic response in severe aplastic anemia
• ESC position paper addresses cardiotoxicity of cancer therapies
• Extended hormone therapy prolongs DFS, maintains quality of life
• First-line nivolumab fails to prolong PFS for advanced PD-L1–positive NSCLC
• Hydroxyurea shows promise for stroke prevention in pediatric patients with sickle cell anemia
• Midostaurin confers OS, EFS benefits in FLT3-mutated AML
• Neoadjuvant ado-trastuzumab emtansine, pertuzumab increases pathologic complete response in HER-2–positive breast cancer
• Novel BRCA testing model reduces wait, increases patient satisfaction
• Pembrolizumab active in cisplatin-ineligible advanced urothelial cancer
• Recombinant Factor VIII products increase inhibitor development in severe hemophilia A
• Ability to harness immune system may provide urgently needed therapies for pancreatic cancer Jai N. Patel, PharmD, BCOP, CPP
• Should stereotactic body radiation therapy be adopted as a standard of care for patients with locally advanced pancreatic cancer?